Objective: To provide a description of our transsexual population. Method: This descriptive observational study included 138 patients with a diagnosis of Transsexualism in Brazil, between March 1998 and September 2005. Demographic, clinical and psychiatry data were collected.Results: Age ranged from 16 to 54 years; 88.4% were male. The prevalence of sexually transmitted diseases was 19.5%, and 17.6% were HIV-positive. Hormone therapy was reported by 91.2%, and 47.4% referred drug and alcohol use; 14.2%, attempted suicide; and 12.5%, history of sexual abuse. Self-mutilation was reported by 5.2%s. Fifty-nine patients (42.7%) had at least one currently psychiatric comorbidity (axis I or II).Conclusions: Mental health professionals have a central role in coordinating the multidisciplinary care of transsexuals.
Objective: To evaluate the impact of sex reassignment surgery on the defense mechanisms of 32 transsexual patients at two different points in time using the Defensive Style Questionnaire. Method: The Defensive Style Questionnaire was applied to 32 patients upon their admission to the Gender Identity Disorder Program, and 12 months after they had undergone sex reassignment surgery. Results: There were changes in two defense mechanisms: anticipation and idealization. However, no significant differences were observed in terms of the mature, neurotic and immature categories. Discussion: One possible explanation for this result is the fact that the procedure does not resolve gender dysphoria, which is a core symptom in such patients. Another aspect is related to the early onset of the gender identity disorder, which determines a more regressive defensive structure in these patients. Conclusion: Sex reassignment surgery did not improve the defensive profile as measured by the Defensive Style Questionnaire.
Rev Bras Psiquiatr. 2005;27(4):341-8 346 Cartas aos editores escala, o propranolol (aproximadamente seis meses). Efeitos colaterais e tóxicos impediram o aumento delas e parece que, com o tempo, M. desenvolveu certa tolerância ao seu efeito. Com a introdução de 150 mg de topiramato/dia (50 mg 3x/dia), os níveis de irritabilidade e agressividade caíram muito, o que permitiu a redução e a retirada de outras medicações concomitantes. Já temos hoje um seguimento de nove meses e não houve, até o momento, o desenvolvimento de tolerância, como ocorreu com a clorpromazina e com o propranolol. O paciente, no momento, está em monoterapia com topiramato, 50 mg, 3x/dia. Eventualmente, quando necessita de um hipnótico, utiliza-se lorazepam 3 mg ao deitar. Assim, o topiramato mostrou-se uma medicação muito efetiva na redução da agressividade, irritabilidade auto e heterodirigida em uma criança autista. Ao nosso conhecimento, este é o primeiro relato da utilização exitosa do topiramato na agressividade/irritabilidade de pacientes com autismo automutilatório severo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.